Oncosyne provides world-leading predictive tumoroid drug screening tools for colorectal and pancreatic cancer, creating new opportunities for pharma companies to accelerate drug discovery and development and for oncologists to select the best drug for each patient. Oncosyne’s tumoroid platform iCAN is a groundbreaking innovation poised to take precision medicine to the next level. iCAN is marketed for drug discovery and development and is under development for predictive diagnostics in cancer care. Our vision is to provide game-changing, functional diagnostic tools that help give cancer patients significantly better and longer lives across the globe.